Koss Olinger Consulting LLC Has $2.31 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Koss Olinger Consulting LLC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,378 shares of the medical equipment provider’s stock after purchasing an additional 454 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Zimmer Biomet were worth $2,306,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Zimmer Biomet by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock worth $2,609,130,000 after purchasing an additional 166,763 shares during the last quarter. Dodge & Cox increased its position in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock worth $2,019,480,000 after purchasing an additional 2,044,645 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock worth $1,559,147,000 after purchasing an additional 176,337 shares during the last quarter. Northern Trust Corp increased its position in shares of Zimmer Biomet by 7.6% during the 4th quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider’s stock worth $250,367,000 after purchasing an additional 167,435 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Zimmer Biomet by 6.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,000,838 shares of the medical equipment provider’s stock worth $211,348,000 after purchasing an additional 126,151 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on ZBH shares. UBS Group set a $96.00 price target on Zimmer Biomet and gave the stock a “sell” rating in a research report on Friday. Robert W. Baird lowered their price target on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. JMP Securities decreased their target price on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. Wells Fargo & Company decreased their target price on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Finally, Morgan Stanley decreased their target price on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $111.44.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $99.14 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 1.46. The stock’s fifty day moving average price is $93.34 and its two-hundred day moving average price is $99.80. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The firm has a market cap of $19.61 billion, a price-to-earnings ratio of 24.12, a P/E/G ratio of 2.30 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same period in the prior year, the firm posted $2.01 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 26th. Zimmer Biomet’s dividend payout ratio is presently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the company’s stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.39% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.